Hematologic Responses Achieved with Luspatercept in Higher-Risk Myelodysplastic Syndromes.
Saved in:
| Title: | Hematologic Responses Achieved with Luspatercept in Higher-Risk Myelodysplastic Syndromes. |
|---|---|
| Authors: | Leonard D; Massachusetts General Hospital, United States., Sallman DA; Moffitt Cancer Center and Research Institute, Tampa, Florida, United States., Pugh K; The Ohio State University, Columbus, Ohio, United States., Bell C; Oregon Health and Science University, Portland, Oregon, United States., Al Ali NH; Moffitt Cancer Center, Tampa, Florida, United States., Borate U; The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States., Komrokji RS; H. Lee Moffitt Cancer Center, Tampa, Florida, United States., Brunner AM; Leukemia Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, United States. |
| Source: | Blood advances [Blood Adv] 2026 Jun 04. Date of Electronic Publication: 2026 Jun 04. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
